Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team

CAMBRIDGE, Mass. — Nov. 13, 2018 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials. Deya Corzo, M.D., FACMG, joins the company as Chief Medical Officer; Olivia G. Kelly, Ph.D., is Vice President of Islet Cell Therapy Research; Martha Rook, Ph.D., is Head of Manufacturing; and Vanya Sagar joins as Vice President of HR.

“Sigilon’s rapid growth and numerous achievements over the past year and a half have been thanks to our exceptionally talented team — and the addition of Deya, Olivia, Martha and Vanya will deeply enrich our efforts and accelerate our progress,” said Rogerio Vivaldi, M.D., MBA President and Chief Executive Officer of Sigilon. “Their wealth of experience in cell therapy drug development, clinical operations, corporate growth and culture, and cell and gene therapy manufacturing will be assets in our work to create functional cures for chronic diseases using Shielded Living Therapeutics.”

Deya Corzo, M.D., FACMG
Dr. Corzo, Sigilon’s Chief Medical Officer, is a board-certified physician of clinical genetics with decades of experience in directing clinical development of novel therapeutics. Most recently, Dr. Corzo served as Senior Vice President of R&D and Chief Medical Officer at Sojournix, a privately held company focused on developing women’s health products. Before Sojournix Dr. Corzo held leadership positions at uniQure, Celgene, Takeda and Sanofi/Genzyme, in which capacities she directed the development of numerous therapeutics through clinical trials. Dr. Corzo is an instructor of medicine at Harvard Medical School and an attending physician in clinical genetics at Boston Children’s Hospital. Dr. Corzo received a cum laude M.D. degree from the Universidad Industrial de Santander (Colombia) and she completed a research fellowship in immunogenetics at the Dana-Farber Cancer Institute and a clinical fellowship in genetics at Boston Children’s Hospital/Harvard Medical School. Her residency in pediatrics took place at Maimonides Medical Center (Brooklyn, NY).

Olivia G. Kelly, Ph.D.
Dr. Kelly brings to the role of Vice President of Islet Cell Therapy Research over 13 years of experience in the biotechnology industry developing cell therapies. Prior to joining Sigilon, Dr. Kelly served as the Senior Director of Cell Biology at ViaCyte, a clinical stage company focused on developing stem cell-derived therapies for diabetes. Dr. Kelly earned a B.S. in molecular biology from the University of Texas at Austin and then pursued a Ph.D. in biochemistry and molecular biology from Harvard University, where her research focused on molecular mechanisms of early embryonic patterning and pancreas development. Dr. Kelly’s postdoctoral fellowships at the University of California at Berkeley/San Francisco and Baylor College of Medicine focused on signaling mechanisms that regulate the development of various tissues and stem cell differentiation.

Vanya Sagar
Ms. Sagar joins Sigilon as Vice President of HR with more than a decade of experience in HR and operations in industry and academia. Most recently, Ms. Sagar served as HR Business Partner for the Research and Early Development organization at Biogen and prior to that, as the HR Business Partner for the global Finance organization. Before her time at Biogen, Ms. Sagar spent 10 years at Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School in various roles supporting the department of Neurology, including recruitment, on-boarding, training, performance evaluations and program administration, among others. Ms. Sagar holds a bachelor’s degree in Counseling from Dominion College and a Master’s of Public Administration from Suffolk University.

Martha Rook, Ph.D.
Dr. Rook, Sigilon’s Head of Manufacturing, brings to the role more than 20 years of academic and industry experience in molecular biology, diagnostics development and cell and gene therapy manufacturing. Prior to joining Sigilon, Dr. Rook was VP and Head of the Gene Editing & Novel Modalities Business of MilliporeSigma. There she led a team developing and providing tools and services for cell and gene therapies from discovery to manufacturing. Dr. Rook received her Ph.D. in biochemistry from MIT and holds a B.S. in chemistry from Texas A&M University. She pursued post-doctoral studies in neuroscience as a Lefler Fellow at Harvard Medical School’s Center for Neurologic Diseases.

About Sigilon Therapeutics

Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics. To create Shielded Living Therapeutics, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body. These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Sigilon Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa

Cambridge, Mass. — Oct. 1, 2018 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops shielded living therapeutics, today announced that two members of its executive leadership team will present at the 2018 Cell & Gene Meeting on the Mesa in La Jolla, California.

Chief Executive Officer Rogerio Vivaldi will provide an overview of the company and its pioneering work in living therapeutics in his presentation on Thursday, October 4, 2018 at 1:45pm PT/4:45 pm ET.

Chief Strategy Officer and Head of Operations Devyn Smith will speak to challenges related to global supply of cell therapies at the “Readiness Strategies for Cell Therapy Commercial Manufacturing” workshop on Thursday, October 4, 2018 at 7:45am PT/10:45am ET.

A live video webcast of the presentations will be available at http://www.meetingonthemesa.com/webcast/.

About Sigilon Therapeutics

Sigilon Therapeutics is creating a new class of living therapeutics to transform the lives of patients with a wide range of chronic diseases, including hemophilia, Type 1 diabetes and lysosomal storage disorders. Our proprietary platform is designed to restore healthy cell and organ function through the implantation of immune-shielded and specially engineered cells in a matrix optimized for cell survival and durability. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer

Cambridge, Mass. –Aug. 14 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutics, today announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer. Dr. Vivaldi joins the Sigilon team from Bioverativ, a Sanofi company. Paul Wotton, Ph.D., who has stepped back from the role of CEO to manage a family health issue, will remain with the company in an advisory capacity and will continue to hold a seat on the company’s board.

“We thank Paul for his leadership through Sigilon’s first phase of growth, establishing a firm footing for the company’s product platform, building a product pipeline, securing and developing a significant pharma partnership and attracting a top-notch leadership team,” said Doug Cole, M.D., Managing Partner at Flagship Pioneering and Chairman of the Board at Sigilon. “We welcome Rogerio to lead Sigilon’s next phase of growth. His deep therapeutic and commercial experience, expertise and viewpoint across various therapeutic modalities and drug development will be invaluable to building Sigilon to its full potential.”

Founded by Flagship Pioneering in 2016, Sigilon has grown rapidly and marked promising milestones in the development of its Living Therapeutics product platform. Sigilon’s platform represents an unprecedented opportunity to treat previously untreatable conditions with long-lasting cell therapies that can safely exist within the body. The company’s Afibromer™ technology—which does not trigger fibrosis, the body’s natural protective response to foreign objects—represents a new class of breakthrough implantable biomaterials. Engineered cells inside these Afibromer capsules secrete therapeutic cell proteins, providing patients safe and long-lasting treatment for chronic diseases.

“I’ve been privileged to work alongside a talented team as we designed the company for success. The company has achieved promising milestones in multiple therapeutic areas and is in a strong position for the future,” said Dr. Wotton. “I am excited that Rogerio has joined Sigilon and look forward to seeing the company’s growth under his leadership.”

Under Dr. Vivaldi’s leadership, Sigilon plans to move into the clinic and toward regulatory approval and commercialization of its multi-product pipeline. The company also plans to expand into new therapeutic disease areas, beyond its initial pipeline in diabetes, hemophilia and lysosomal storage disorders.

“Sigilon’s platform represents exciting new opportunities for patients with hematologic, enzyme deficiency, endocrine and metabolic disorders—and this is just the beginning,” said Dr. Vivaldi. “I look forward to advancing the company’s vision, mission and promising pipeline to meaningfully impact the lives of people with chronic and serious disorders.”

An industry veteran and a rare disease pioneer with more than 25 years of experience, Dr. Vivaldi joins Sigilon with significant clinical and business experience. Dr. Vivaldi is a trained physician who spent 18 years caring for patients, specializing in endocrinology. Most recently, Dr. Vivaldi was Executive Vice President, Chief Global Therapeutic Operations Officer at Bioverativ, which was acquired by Sanofi in 2018. He has also held leadership roles at Spark Therapeutics and Genzyme. Dr. Vivaldi also co-founded and served as CEO of Minerva Therapeutics, a clinical-stage company developing products for patients with neuropsychiatric diseases. He holds a medical degree from the Universidade do Rio de Janeiro Medical School. He completed a residency in endocrinology at Universidade do Estado do Rio de Janeiro and a fellowship at Mount Sinai Hospital Center in New York in the department of genetics. He also holds an MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro.

To learn more about Sigilon and to read Dr. Vivaldi’s full bio, please visit the company’s website at www.sigilon.com

 

About Sigilon Therapeutics

Founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes

INDIANAPOLIS and CAMBRIDGE, Mass., April 4, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon is a privately-held biopharmaceutical company that is focused on discovering and developing “living therapeutics” with its Afibromer™ technology product platform. Lilly is a global biopharmaceutical company and a worldwide leader in diabetes care, offering a wide range of therapies and a strong commitment to cutting-edge research.

Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. This approach holds promise to address chronic conditions, such as type 1 diabetes. In type 1 diabetes, pancreatic beta cells are destroyed by the immune system, leading to hyperglycemia (high blood sugar) and long-term complications if glucose levels are not managed effectively.

In the Lilly-Sigilon collaboration, Sigilon will create proprietary products comprised of induced pluripotent stem cells, a type of stem cell derived from adult cells, engineered into differentiated insulin-producing pancreatic beta cells and encapsulated using Sigilon’s Afibromer technology. The goal of these products will be to restore insulin production over sustained periods, without triggering an immune reaction.

Research leading to the discovery of Afibromer biomaterials was funded by grants from JDRF International and the Leona M. Helmsley and Harry B. Helmsley Charitable Trust and conducted under the leadership of Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology and Boston Children’s Hospital.

“At Lilly, we endeavor to change the frontiers of what’s possible in medicine, both through our own scientific labs and in collaboration with other leading researchers,” said Daniel Skovronsky, M.D., Ph.D., senior vice president for clinical and product development and incoming president of Lilly Research Labs. “We are excited to be collaborating with, and investing in, Sigilon as they seek to develop encapsulated cell therapies, a potentially disruptive technology that could result in meaningful clinical advancements for chronic diseases such as type 1 diabetes.”

“We are very pleased to partner with Lilly, a worldwide leader in diabetes care, as we seek to apply Sigilon’s game-changing technology to the area of insulin-dependent diabetes,” commented Paul Wotton, Ph.D., Chief Executive Officer of Sigilon Therapeutics. “At Sigilon, published studies have shown the ability to overcome the immune foreign body response with our proprietary Afibromer technology. This holds the promise for the creation of state-of-the-art allogeneic cell factories to be transplanted into patients, without the need for immune suppression. Our cell engineering and delivery system-based platform may allow us to program and control dynamic protein delivery for the long-term treatment of debilitating diseases.”

Under the terms of the agreement, Lilly will receive an exclusive worldwide license to Sigilon’s Afibromer technology for islet cell encapsulation. Sigilon will receive an upfront payment of $63 million and Lilly will make an undisclosed equity investment in Sigilon. Sigilon is also eligible to receive up to $410 million in development and commercialization milestones, as well as single to double digit tiered royalties on future product sales should the collaboration yield a commercially successful product. Sigilon will be responsible for all development activities and costs related to the collaboration until submission of an investigational new drug application (IND). After an IND is submitted, Lilly will be responsible for all clinical development and commercialization activities and costs related to the collaboration.

Sigilon was founded and created by Flagship Pioneering, a life science innovation firm, which unveiled the company in 2017 with $23.5 million in capital. Doug Cole, Managing Partner at Flagship Pioneering and Chairman of Sigilon’s Board added, “We believe that unprecedented innovation, such as that at Sigilon, is necessary to uncover new solutions for patients. Sigilon’s product platform offers the possibility of realizing the full potential of cell therapies, and we look forward to seeing the outcome of Lilly’s and Sigilon’s collaboration for type 1 diabetes.”

As a result of this transaction, Lilly will incur an acquired in-process research and development charge to earnings of approximately $0.05 per share in the second quarter of 2018. The company’s reported earnings per share guidance for 2018 is expected to be reduced by the amount of the charge. There will be no change to the company’s non-GAAP earnings per share guidance as a result of this transaction.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

About Sigilon Therapeutics
Founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life. For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

C-LLY

Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and Sigilon, and reflects Lilly’s current beliefs.  However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, please see Lilly’s most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Refer to:

Mark Taylor; mark.taylor@lilly.com; 317-276-5795 (Lilly Media)   

Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Lilly Investors)     

David Schull; david.schull@russopartnersllc.com; (212) 845-4271 (Sigilon Media Contact)

Sigilon Therapeutics Receives Advanced Therapy Medicinal Product Designation for Afibromer™-Based Living Therapeutic Program

CAMBRIDGE, Mass., March 8, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency. The recommendation, adopted by the committee on Nov. 9, 2017, applies to allogeneic cells genetically modified to express human factor IX protein embedded in the Afibromer™ biomaterial and used for the long-term treatment of patients with hemophilia B.

“This first ATMP classification for our platform technology is an important step in engaging with regulatory authorities for this entirely new category of genetically engineered cell factory therapeutics and is a critical step toward commercialization in Europe for advanced therapies like SIG-003,” commented Paul Wotton, Ph.D., Chief Executive Officer of Sigilon Therapeutics. “As we proceed in development, it is critical that we work with regulators to define a clear path toward market approval from the earliest stages, which includes satisfying established international guidelines and standards for the future introduction of new Living Therapeutics.”

ATMP classifications are granted for new therapeutics which fulfill the definitions for medicinal products that are gene therapy, somatic cell therapy and/or tissue engineered products. The ATMP classification provides regulatory guidelines for preclinical development, manufacturing and product quality testing. The regulation also offers incentives including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data. Additional information on the ATMP confirmation can be found at the European Medicines Agency website at www.ema.europa.eu/ema.

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

Sigilon Therapeutics to Present at Cowen & Company 38th Annual Health Care Conference

CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference. Presentation details are as follows:

Cowen & Company 38th Annual Health Care Conference

Presenter:                          Paul Wotton, Ph.D., Chief Executive Officer

Date:                                   Monday, March 12, 2018

Time:                                   10 a.m. EDT

Location:                            Boston Marriott Copley Place

About Sigilon Therapeutics

 Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

 Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

Sigilon Therapeutics to Present at Upcoming Conferences

CAMBRIDGE, Mass., Feb. 8, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:

BIO CEO & Investor Conference 2018

Presenter:                        Paul Wotton, Ph.D., Chief Executive Officer
Date:                                Monday, Feb. 12, 2018
Time:                               10:15 a.m. EST
Location:                          Room Gilbert, New York Marriott Marquis Hotel, New York

Biocom Global Life Science Partnering Conference 2018

Panel presentation:         What to Expect in Business Development: 2018 & Beyond
Presenter:                        David Moller, M.D., Chief Scientific Officer
Date:                                Thursday, March 1, 2018
Time:                                8:30 a.m. PST
Location:                          Maurice Braun ballroom, The Lodge at Torrey Pines Hotel, La Jolla, CA

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrineand metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

Elsevier welcomes six biotech and pharma starts-ups to The Hive

Elsevier welcomes six biotech and pharma start-ups to The Hive, supporting the most cutting-edge research in industry

Start-ups working on a range of technologies and discoveries – from AI to immunotherapy – receive complimentary access to Elsevier’s information solutions to accelerate innovation

Share this:

New York, January 31, 2018
Elsevier, the global information analytics business specializing in science and health, today announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier’s innovation initiative for biotech and pharmaceutical start-ups.
Exscientia, LegoChem Biosciences, 4P-Pharma, Beacon Discovery, Sigilon Therapeutics, and Unum Therapeutics, were selected for their commitment to cutting-edge science in emerging areas of research; all six demonstrate significant potential to impact how future treatments are researched and developed. As members of The Hive, each company will receive support, complimentary training, and access to Elsevier’s suite of information solutions for 18 months.
“As the pharma ecosystem grapples with how to incorporate artificial intelligence (AI) into R&D, or how to accelerate the discovery of new biologics and immunotherapies, start-ups around the globe are playing a pivotal role,” said Betsy Davis, Senior Strategic Marketing Manager at Elsevier. “We received more than three times the number of applications than in 2016 – underlining the importance that start-ups place on the role of discovery solutions in innovation.”
“This year, to demonstrate the vast contribution of start-ups in the origin of drug discoveries, we will especially focus on helping these companies close the gap between concept and commercialization – particularly for start-ups from academic backgrounds. And we look forward to sharing the stories of these dynamic, exciting biotech start-ups with a global audience,” Ms. Davis said.
The goal of The Hive is to help foster the discoveries that happen in these early stages, start-up environments, ensuring that the route to market for new innovations is accelerated. The six participating companies – the second intake of start-ups to The Hive – will use Elsevier’s tools to support their groundbreaking and innovative work in some of the hottest research areas, including:
Exscientia, from Scotland, UK; uses systems driven by AI to actively learn best practices from vast repositories of discovery data, and design millions of novel, project-specific compounds; Exscientia is the first company to automate drug design
LegoChem Biosciences, from South Korea (the first Hive participant from Asia); develops Antibody-Drug Conjugates (ADC) utilizing its proprietary ADC platform ConjuAllTM, which provides solutions for major unmet needs in ADC development
4P-Pharma, from France; bridges the gap between academic discoveries and the pharma industry, helping to mature early-stage technologies from the drug discovery level to clinical phase and commercialization
Beacon Discovery, from San Diego, CA, USA; composed of a group of scientists who have worked together for more than a decade; leverages academic and pharma partnerships to advance research around translating G-Protein Coupled Receptors into new therapeutics
Sigilon Therapeutics, from Cambridge, MA, USA; develops treatments based on a platform enabling a new therapeutic modality for chronic diseases that are currently treated with intermittent injection or infusion in order to restore health and improve quality of life
Unum Therapeutics, from Cambridge, MA, USA; develops novel immunotherapy products based on its universal Antibody-Coupled T-cell Receptor (ACTR). Unlike other approaches, its therapies are not restricted to a particular target and may be used in many different cancer types
“Being part of The Hive will increase the efficiency of our team’s research and development activities. Access to Elsevier’s R&D information and solutions will be a real boost to help us in achieving our aim of developing a new blockbuster drug,” said Yong-Zu Kim, CEO and President, LegoChem Biosciences.
Elsevier’s suite of R&D Solutions fuels research and decision-making in early stage drug discovery and development, and are used by most of the world’s leading biopharmaceutical companies. The products that The Hive participants will be using include: Pathway Studio™, Reaxys®, Reaxys® Medicinal Chemistry, ScienceDirect, Scopus, PharmaPendium®, and Embase®. The Hive, which first launched in 2016 with four start-ups selected to take part, engages the global pharma community via content featuring the participants, which will be widely-promoted throughout Elsevier’s online and social networks.
“At Exscientia, we apply AI algorithms to drug design – one of our biggest challenges is systematic access to high quality data. As such, being part of The Hive and using a range of Elsevier’s tools will help us drive our research forward,” said Andrew Hopkins, CEO, Exscientia. “For example, patent data in Reaxys will support better model building and evaluation of novelty, and Pathway Studio will give us deep visibility into disease pathways. We look forward to working with Elsevier within The Hive to achieve our goals and uncover new commercial applications.”
For more information please visit: www.elsevier.com/thehive.

About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Media contact
Christopher Capot, Director, Corporate Relations
Elsevier
+1 917 704 5174
c.capot@elsevier.com

Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged Living Therapeutics, today announced the appointment of David E. Moller, M.D., to the position of Chief Scientific Officer. Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.

“Dr. Moller’s experience provides an ideal fit for the Sigilon leadership team as we explore the broad therapeutic applications of our Afibromer™-based Living Therapeutics platform, using proprietary engineered cells as protein factories within the body,” commented Paul Wotton, Ph.D., Chief Executive Officer of Sigilon Therapeutics. “We are pleased to have Dr. Moller join us at this time in our growth to develop the many potential applications of this new approach to therapy.”

“I am thrilled to join Sigilon Therapeutics at this point in its rapid growth to drive the identification and implementation of new pipeline and platform opportunities,” added Dr. Moller. “During my career I’ve been fortunate to investigate and develop several novel therapies. I’m particularly excited about the opportunity to now join a company that is poised to revolutionize the way that proteins are delivered —continually manufactured in the body by programmable cell implants — to treat numerous serious diseases.”

Dr. Moller was previously Vice President of Business Development – Emerging Technology and Innovation at Eli Lilly, evaluating applications of breakthrough biology across multiple therapeutic areas. As Vice President of Endocrine and Cardiovascular Research and Clinical Investigation at Eli Lilly, Dr. Moller was responsible for discovery and early drug development in diverse therapeutic areas; his team delivered several key additions to the pipeline including dulaglutide (Trulicity™). Prior to joining Eli Lilly, Dr. Moller led global discovery efforts in diabetes and obesity as Vice President, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia™). Before moving to industry, Dr. Moller was on the faculty of Harvard Medical School. Dr. Moller completed a residency in Internal Medicine at George Washington University, received his medical degree from the University of Cincinnati and earned a B.S. from Brown University.

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

SOURCE Sigilon Therapeutics

Related Links

Home

Sigilon Therapeutics to Present at Upcoming January Conferences

CAMBRIDGE, Mass., Jan. 2, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in January. Presentation details are as follows:

Biotech Showcase 2018

Presenter:

Paul Wotton, Ph.D., Chief Executive Officer

Date:

Monday, Jan. 8, 2018

Time:

1:45 p.m. PST

Location:

Room Franciscan C, Hilton San Francisco Union Square Hotel

Cell & Gene Therapy World 2018

Presenter:

David Peritt, Ph.D., Chief Technology Officer

Date:

Wednesday, Jan. 24, 2018

Time:

2:35 p.m. EST

Location:

Hyatt Regency Miami

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

SOURCE Sigilon Therapeutics

Related Links

Home

Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017

Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017

Presentations by Robert Langer and Daniel Anderson Followed by Interactive Q&A Session Open to the Public Moderated by Journalist Luke Timmerman

CAMBRIDGE, Mass., Nov. 30, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that it will host a live, online educational webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Monday, Dec. 4, 2017, at 10 a.m. EST. Following presentations by Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Sigilon scientific advisory board, journalist Luke Timmerman will moderate a discussion of questions submitted by audience participants on current methods and promising new protein delivery technologies.

“Significant progress continues to be made towards the development of therapeutic technologies that can replace or produce proteins from within the body,” said Dr. Langer. “Our goal is to restore the natural protein function in the body and thereby provide significant therapeutic benefits to patients.”

The presentations will review current methods of protein delivery, provide historical background on the development of new methods, and compare methods including gene therapy, gene editing and implanted engineered cell therapies that are related to the academic and translational research of Dr. Langer and Dr. Anderson. Participation is open to members of the public at no cost.

Webinar Information

Participants can register in advance and access the webinar at: https://www.webcaster4.com/Webcast/Page/754/23361. Participants are encouraged to log on within 15 minutes prior to the beginning of the webinar. Following the event, a replay of the event will be available on the Sigilon website.

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

 Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

 

Sigilon Therapeutics to Present at the 2017 Biotech and Money Inv€$tival Showcase Conference in London

CAMBRIDGE, Mass., Nov. 10, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017. Details are as follows:

Date:                  Tuesday, Nov. 14, 2017
Time:                  11:45 a.m. GMT
Location:            The Hilton Waldorf Hotel, London

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

Sigilon Therapeutics Appoints Eric Shaff to Board of Directors

CAMBRIDGE, Mass., Nov. 1, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the appointment of Eric Shaff, Chief Financial Officer of Seres Therapeutics (NASDAQ:MCRB), to the Sigilon Therapeutics board of directors. Mr. Shaff brings a long history of industry experience to the company’s board.

“Mr. Shaff’s experience in company building, finance, and corporate development, notably in emerging areas of biotechnology, will be particularly helpful as we develop a new Afibromer™ cell factory approach to the treatment of chronic diseases,” said Douglas Cole, M.D., Chairman of the Board of Sigilon Therapeutics. “We are pleased that Mr. Shaff will share his perspectives and experience as a member of the board and appreciate his recognition of the promise of Sigilon’s technology platform.”

Mr. Shaff commented, “I am excited to contribute to the Company’s plans to harness the full power of ‘living therapeutics’ to make a meaningful difference for patients with serious and chronic unmet needs.”

Eric Shaff is Executive Vice President and Chief Financial Officer of Seres Therapeutics, a role that follows a series of leadership positions in corporate finance in the biopharmaceutical industry. Prior to Seres, Mr. Shaff worked at Momenta Pharmaceuticals and Genzyme Corporation, where he served as global head of finance of Genzyme’s Rare Genetic Disease Division in addition to roles in corporate development and corporate finance. Mr. Shaff has also worked in corporate finance at Pfizer and in investment banking with Broadview International (now Jefferies Broadview). Mr. Shaff earned a B.A. from the University of Pennsylvania and holds an M.B.A. from the Johnson Graduate School of Management at Cornell University.

About Sigilon Therapeutics  

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer ™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Sigilon Therapeutics’ co-founders include Daniel Anderson, Ph.D., and Robert Langer, Sc.D. of MIT’s Institute of Medical Engineering and Science, Department of Chemical Science and Koch Institute; Omid Veiseh, Ph.D., of Rice University; José Oberholzer, M.D., of the University of Virginia; and Arturo Vegas, Ph.D., of Boston University.

 

For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

Sigilon Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Sept. 29, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present an overview of the company’s development programs at the Cell & Gene Meeting on the Mesa to be held Oct. 4-6, 2017, in La Jolla, California. Presentation details are as follows:

 

Date:                    Thursday, Oct. 5, 2017

Time:                    1:15 p.m. PDT

Location:             Estancia La Jolla Hotel & Spa, La Jolla, California

 

About Sigilon Therapeutics

 

Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials developed at the Massachusetts Institute of Technology that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics’ technology platform include cell implants that act as “protein factories” and responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

 

For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.

 

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

 

Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com

Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer Encapsulated Cell Therapies

Category-defining platform to engineer biocompatible encapsulated cell therapeutics to treat serious diseases

Company assembles leadership team with extensive success in cell biology, translational materials science, medical research and biopharmaceutical development

Cambridge, Mass. – June 21, 2017 – Flagship Pioneering, a fully-integrated life science innovation enterprise, today announced the launch of Sigilon Therapeutics Inc. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer technology, a new class of implantable biomaterials that do not trigger fibrosis. The company will develop products that emerge from its discovery platform to treat serious hematologic, enzyme deficiency and endocrine disorders. VentureLabs®, Flagship’s institutional innovation foundry, originated Sigilon Therapeutics and co-founded the company with Professors Daniel Anderson and Robert Langer of MIT’s Institute of Medical Engineering and Science, Department of Chemical Engineering and Koch Institute. Flagship capitalized Sigilon Therapeutics with $23.5 million.

Fibrosis—a scarring process by which the body isolates foreign material—has historically prevented the successful development of encapsulated cell therapies. Capsules made with biocompatible Afibromers demonstrate unprecedented cell survival and function for extended periods. Sigilon Therapeutics engineers the cells in these capsules to secrete therapeutic proteins continuously and consistently. Afibromers are based on research led by Professor Anderson, whose studies describing the results of this work have been published in Nature Materials, Nature Medicine and Nature Biotechnology.

“Harnessing the power of cells to treat diseases has been a holy grail for medicine since the advent of biotechnology. It opens the possibility of treating patients with serious illnesses without the risks of immunosuppression or genetic manipulation,” said Douglas Cole, M.D., managing partner at Flagship Pioneering and founding chairman of the Sigilon Therapeutics board of directors. “Following two years of forming the innovation and IP foundations within Flagship VentureLabs, Sigilon Therapeutics is poised to leverage its unique approach to engineering controllable and dose-adjustable cell systems to provide a natural, effective form of delivery that vastly expands therapeutic options for patients and physicians.”

Professor Robert Langer, a co-founder and director of Sigilon Therapeutics, said, “Restoring critical proteins in the body in an effective and controllable way has been an elusive goal for many years. The discovery of permeable biomaterials that avoid fibrosis opens a broad range of possibilities. Sigilon Therapeutics’ technology allows implanted cells to deliver proteins in a controlled manner over extended periods and can be envisioned as a transplanted tissue that avoids effects of rejection and isolation by the immune system.”

Sigilon Therapeutics also today announced its executive leadership and board of directors, both of which comprise executives with extensive backgrounds in cell biology, translational materials science, medical research and biopharmaceutical development for new types of therapeutics.

“Imagine the potential of a ‘living therapeutic’ that could be implanted in the body and manufacture and release therapeutic proteins at steady levels for long periods of time, avoiding the critical limitations of intermittent infusion required with current therapies,” said Paul K. Wotton, Ph.D., CEO and member of the board of directors. “Our proprietary approach to cell engineering and Afibromer technology, together with the deep experience of our leadership, allows us to realize this potential and restore health and quality of life for many patients.”

About Sigilon Therapeutics’ Leadership Team and Board of Directors
Prior to becoming CEO at Sigilon Therapeutics, Dr. Wotton served as president and CEO of Ocata Therapeutics until its acquisition by Astellas Pharma, where he was co-chairman of the Integration Management Office. He has also served as president and CEO of Antares Pharma as well as CEO of Topigen Pharmaceuticals. Dr. Wotton has held senior leadership roles at SkyePharma, Eurand International, Penwest Pharmaceuticals, Abbott Laboratories as well as Merck and Sharp & Dohme (Merck & Co.) Dr. Wotton received a Ph.D. in pharmaceutical science from the University of Nottingham and is the recipient of the 2014 EY Entrepreneur of The Year Award (NJ) in Life Sciences.

Sigilon Therapeutics has assembled an executive team with many years of experience in their respective areas of expertise. This group includes Chief Technology Officer David Peritt, Ph.D., who has recently joined from Pfizer, and Chief Strategy Officer and Head of Operations Devyn Smith, Ph.D., who was previously head of operations and strategy for the Medicinal Sciences Division of Worldwide R&D at Pfizer. James D. Watson, chief business officer of Sigilon Therapeutics, previously served as CBO at Alvine Pharmaceuticals and has held leadership roles at Burrill & Company and Incyte Corporation.

The Sigilon Therapeutics board of directors is led by Chairman Douglas Cole, M.D., managing partner at Flagship Pioneering. Other members of the board of directors include Jim Gilbert, senior partner at Flagship Pioneering; Robert Langer, Sc.D., David H. Koch Institute Professor at MIT; Daniel G. Anderson, Ph.D., professor of chemical engineering at MIT; Robert Ruffolo, Ph.D., former president of research and development at Wyeth Pharmaceuticals and recipient of the Scrip Lifetime Achievement Award; Jeff Flier, M.D., professor at the Harvard Medical School and former dean of the faculty of medicine at Harvard University; and Stephen Oesterle, M.D., former senior vice president for medicine and technology at Medtronic.

About Sigilon Therapeutics
Sigilon Therapeutics was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics’ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

In addition to Flagship Pioneering, Professor Anderson and Professor Langer, Sigilon Therapeutics’ co-founders include Omid Veiseh, Ph.D., José Oberholzer, M.D. of the University of Virginia, and Arturo Vegas, Ph.D. of Boston University.

For more information please visit www.sigilon.com.

About Flagship Pioneering
Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. Its institutional innovation foundry, Flagship VentureLabs®, is where Flagship’s team of scientific entrepreneurs systematically evolves enterprising ideas into new fields or previously undiscovered areas of science into real-world inventions and ventures. Since its launch in 2000, the firm has applied its hypothesis-driven innovation process to originate and foster nearly 100 scientific ventures, resulting in over $20 billion in aggregate value, 500+ issued patents and more than 45 clinical trials for novel therapeutic agents.

Since inception, Flagship has capitalized its growing portfolio with over $1 billion coming from $1.75 billion of aggregate investor capital committed across five funds. The firm’s current portfolio includes pioneering ventures that are transforming human health and sustainability, including: Agios Pharmaceuticals (NASDAQ: AGIO), Editas Medicine (NASDAQ: EDIT), Seres Therapeutics (NASDAQ: MCRB) and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies, including Axcella Health, Indigo Agriculture, Moderna Therapeutics and Rubius Therapeutics. Flagship has ongoing corporate innovation alliances with several market leaders, including: AstraZeneca, the Crop Science Division of Bayer and Nestlé Health Science. To learn more about Flagship Pioneering, please visit our website: www.FlagshipPioneering.com.


Sigilon Therapeutics Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

Flagship Pioneering Contact
Genevieve Gadenne
(617) 868-1888
media@flagshippioneering.com

Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com